Sun Country stock in the spotlight after Allegiant’s $1.5 billion deal — what to watch Monday

Sun Country stock in the spotlight after Allegiant’s $1.5 billion deal — what to watch Monday

New York, January 11, 2026, 18:43 (ET) — The market has closed.

  • Allegiant struck a cash-and-stock deal to acquire Sun Country, pricing SNCY at $18.89 per share—a roughly 19.8% premium over Friday’s close
  • Companies project $140 million in annual synergies by the third year after closing and anticipate the deal will boost earnings per share starting in the first year post-close
  • Investors will get their first live update on strategy and integration during a joint call scheduled for Monday, Jan. 12

Sun Country Airlines shares are set for close scrutiny when U.S. markets open Monday, following Allegiant Travel’s agreement to buy the carrier for roughly $1.5 billion, debt included. The deal values Sun Country at $18.89 per share, a roughly 19.8% premium over Friday’s closing price, the companies confirmed. (Reuters)

The deal comes as smaller airlines grapple with revenue that fluctuates sharply with the leisure travel cycle. Allegiant and Sun Country present the merger as a way to create a larger, more agile carrier that can quickly adjust capacity across different routes and seasons.

This is important for Sun Country shareholders as well, since the payout isn’t entirely cash. Part of it comes in Allegiant stock, meaning the deal’s implied value will fluctuate with ALGT shares until it closes.

Sun Country shareholders will get 0.1557 Allegiant shares plus $4.10 cash for every SNCY share, under the deal. Allegiant shareholders are set to hold roughly 67% of the merged entity, while Sun Country investors would own about 33%, the companies said.

The merged airline will be based in Las Vegas and operate roughly 195 planes, including pending orders and options, the companies announced. They added the deal aims to expand their reach across U.S. routes and global markets.

Management projects $140 million in yearly synergies by the third year post-close — a blend of cost savings and revenue boosts they anticipate from the merger. They also indicated the deal should be accretive to earnings per share, meaning it’s expected to increase profit per share starting in the first year after closing.

The companies aim to finalize the deal in the second half of 2026, pending U.S. antitrust approval, other regulatory sign-offs, and shareholder votes. Allegiant Chief Executive Gregory Anderson is set to head the merged firm, with Robert Neal taking on the roles of president and CFO. Sun Country CEO Jude Bricker will join the board.

“This combination is an exciting next chapter” for delivering “affordable, reliable, and convenient service,” Anderson said. Bricker added the deal “marks an exciting next step” and “delivers significant value” to Sun Country shareholders. The companies plan a joint investor conference call Monday, Jan. 12, at 8:30 a.m. ET. (PR Newswire)

Allegiant’s stock climbed 2.7% to finish Friday at $94.97, with Sun Country rising 2.6% to close at $15.77.

Airline deals often hit snags. Regulatory approvals can stall, integration may throw off schedules, and synergy targets remain projections, not certainties—particularly if demand weakens or costs climb faster than expected.

Monday brings the next call along with the first batch of deal filings. Traders will be tracking the stock-and-cash structure closely as soon as the market opens, while investors are likely to push management on timing, approvals, and progress toward hitting those synergy targets.

CEO of TS2 Space and founder of TS2.tech. Expert in satellites, telecommunications, and emerging technologies, covering trends in space, AI, and connectivity.

Stock Market Today

  • Profound Medical: Top TSX Growth Stock Poised for Rapid Expansion, Q3 Revenues Surge 87%
    February 1, 2026, 9:22 PM EST. Profound Medical (TSX:PRN), a Canadian medical device firm specializing in MRI-guided ultrasound therapies, is highlighted as the sole TSX growth stock to hold for the next three years. The company reported an 87% revenue increase in Q3 to $5.3 million, driven by expanded installations of its flagship TULSA-PRO prostate cancer treatment system. Offering incision-free, MRI-guided ablation technology, Profound's procedures have gained Medicare approval with rising insurance reimbursements. Despite a net loss of $8 million, the company improved gross margins to 74.3% and ended Q3 with $25 million cash, supporting near-term liquidity. With 70 systems installed and 93 in advanced sales stages, Profound aims for 75 installations by year-end, making it a notable small-cap growth stock in healthcare on the TSX.
NuScale Power stock set for Monday test after BofA upgrade keeps SMR trade alive
Previous Story

NuScale Power stock set for Monday test after BofA upgrade keeps SMR trade alive

S Chand share price set for Monday spotlight after S$1.5 million Singapore curriculum deal
Next Story

S Chand share price set for Monday spotlight after S$1.5 million Singapore curriculum deal

Go toTop